Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Hisun Pharmaceutical CoSHSE:600267 -1.18%58 Interest Coverage is 21.71 as of Mar. 2026, which is 735% above its 10-year median of 2.60. GuruFocus rates SHSE:600267 with a GF Score™ of 58/100 and a GF Value™ of ¥8.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 687 Drug Manufacturers companies, Zhejiang Hisun Pharmaceutical Co ranks better than 53.86% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zhejiang Hisun Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥363 Mil. Zhejiang Hisun Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-17 Mil.
Zhejiang Hisun Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 21.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's Interest Coverage or its related term are showing as below:
SHSE:600267'
s Interest Coverage Range Over the Past 10 Years
Min: 0.07 Med: 2.6 Max: 15.04
Current: 15.04
SHSE:600267's Interest Coverage is ranked better than 53.86% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs SHSE:600267: 15.04
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zhejiang Hisun Pharmaceutical Co Interest Coverage Related Terms
Zhejiang Hisun Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Zhejiang Hisun Pharmaceutical Co Interest Coverage Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's Interest Coverage falls into.
Zhejiang Hisun Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Interest Coverage of 21.71 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is 735% above median its historical median of 2.60. Over the past decade, Zhejiang Hisun Pharmaceutical Co's Interest Coverage has ranged from 0.07 to 15.04. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #317 out of 687 companies in the Drug Manufacturers industry, placing it in the top 46.1%.
Is Zhejiang Hisun Pharmaceutical Co's Interest Coverage too high?
Zhejiang Hisun Pharmaceutical Co's current Interest Coverage of 21.71 is 735% above median its 10-year median of 2.60. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 15.04. The Drug Manufacturers industry median Interest Coverage is 12.70. Zhejiang Hisun Pharmaceutical Co's value of 21.71 is 70.9% above this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #317 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #317 out of 687 companies for Interest Coverage. This puts Zhejiang Hisun Pharmaceutical Co in the upper half of its industry. The industry median Interest Coverage is 12.70. Zhejiang Hisun Pharmaceutical Co's value of 21.71 is 70.9% above this benchmark. Historically, Zhejiang Hisun Pharmaceutical Co's own Interest Coverage has ranged from 0.07 to 15.04 over the past decade. While the company's 10-year median is 2.60 vs. the industry median of 12.70, Zhejiang Hisun Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current Interest Coverage of 21.71 is 70.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current Interest Coverage is 21.71, which is 735% above median its own 10-year median of 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current Interest Coverage is 21.71, which is 735% above median its 10-year median of 2.60 and 70.9% above the Drug Manufacturers industry median of 12.70. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Interest Coverage is 21.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
Interest Coverage: 21.71 (735% above median its 10-year median of 2.60)
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
Industry Position: 70.9% above the Drug Manufacturers median (#317 of 687)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
